Position in TLRY
as of Jun 30, 2026
· filed Jul 8, 2026
Position Value
$1,347
+$53 QoQ
Shares Held
300
+50.0% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#19
of 50 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in TLRY Over Time
Shares Held
Position Value (USD)
Derivatives in TLRY
reported options exposure · as of Jun 30, 2026CallValue
$2,626
CallShares
585
PutValue
$0
PutShares
0
Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.
Position in Drug Manufacturers - Specialty & Generic
Healthcare · as of Jun 30, 2026FNY Investment Advisers, LLC holds $2,159,974 across 8 Drug Manufacturers - Specialty & Generic names. TLRY ranks #6 (0.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LQDA |
Liquidia Corp
|
17,500 | $1,395,275 | |
| 2 | ESPR |
Esperion Therapeutics, Inc.
|
110,000 | $347,600 | |
| 3 | HIMS |
Hims & Hers Health, Inc.
|
10,010 | $347,046 | |
| 4 | GLAS |
Glass House Brands Inc.
|
5,000 | $65,000 | |
| 5 | CRON |
Cronos Group Inc.
|
1,000 | $2,780 | |
| 6 | TLRY |
Tilray Brands, Inc.
This page
|
300 | $1,347 | |
| 7 | BHC |
Bausch Health Companies Inc.
|
140 | $690 | |
| 8 | AYTU |
Aytu Biopharma, Inc
|
110 | $236 |
All Filings in TLRY
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2,626 | 585 | Call | Sole | 2026-07-08 | |
| 2026-06-30 | $1,347 | 300 | Shares | Sole | 2026-07-08 | |
| 2026-03-31 | $1,294 | 200 | Shares | Sole | 2026-04-15 | |
| 2026-03-31 | $3,687 | 570 | Call | Sole | 2026-04-15 | |
| 2025-12-31 | $1,806 | 200 | Shares | Sole | 2026-01-16 | |
| 2025-12-31 | $4,966 | 550 | Call | Sole | 2026-01-16 | |
| No filing history on record for this holder in this stock. | ||||||